(firstQuint)Pilot Study to Assess the Efficacy and Safety of H.

P.

 Acthar Gel in Subjects With Pulmonary Sarcoidosis.

 This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of Acthar gel in the treatment of pulmonary sarcoidosis.

 All subjects who meet eligibility criteria will be randomly assigned to receive either 1 mL (80 U) of Acthar or 1 mL of a matching placebo subcutaneously (SC) 2 x/week.

 Subjects will be assigned to treatment in a 1:1 ratio with up to 50 subjects per arm for a total of up to 100 subjects.

 Subjects who complete the 24 week randomized, double-blind, placebo-controlled treatment period will be eligible to continue in an optional 24 week open label extension.

.

 Pilot Study to Assess the Efficacy and Safety of H.

P.

 Acthar Gel in Subjects With Pulmonary Sarcoidosis@highlight

The purpose of this study is to evaluate the efficacy and safety of H.

P.

 Acthar(R) Gel (Acthar) in the treatment of pulmonary sarcoidosis.

